Medical

Medical

Cemiplimab With or Without Chemotherapy Provides Long-Term Clinical Benefit in Locally Advanced NSCLC

First-line cemiplimab (Libtayo) monotherapy or in combination with platinum-based chemotherapy conferred long-term clinical benefit to patients with unresectable, locally advanced non–­small cell lung cancer (NSCLC) who were ineligible for concurrent chemoradiation, according to a post-hoc analysis presented at the 2023 European…

Read More